RT Journal Article
SR Electronic
T1 Dupilumab reduces OCS use and improves lung function in patients with severe OCS-dependent asthma
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 3620
DO 10.1183/13993003.congress-2022.3620
VO 60
IS suppl 66
A1 Gurnell, M
A1 Domingo, C
A1 Rabe, K F
A1 Menzies-Gow, A
A1 Price, D
A1 Brusselle, G
A1 Wechsler, M E
A1 Xia, C
A1 Pandit-Abid, N
A1 Gall, R
A1 Jacob-Nara, J A
A1 Rowe, P J
A1 Deniz, Y
A1 Siddiqui, S
YR 2022
UL http://erj.ersjournals.com/content/60/suppl_66/3620.abstract
AB Background Dupilumab (DPL), a fully human anti-IL-4Rα mAb, blocks interleukin-4/13, key and central drivers of type 2 inflammation. TRAVERSE (NCT02134028), a single-arm, open-label extension study, evaluated the long-term safety and efficacy of DPL 300mg q2w for up to 96 weeks in patients (pts) from VENTURE.Aim To assess DPL efficacy in TRAVERSE pts with severe OCS-dependent asthma by OCS dose at parent study baseline (PSBL; VENTURE).Methods Pts from TRAVERSE were analyzed as DPL/DPL or placebo (PBO)/DPL group and stratified by OCS dose (≤10/>10mg/day at PSBL). % reduction in OCS dose and change in pre-BD FEV1 from PSBL at TRAVERSE Weeks (Wks) 0/96; % of pts achieving 0, <5, or <10mg/day OCS; AER during VENTURE and TRAVERSE were assessed.Results 187 pts from TRAVERSE were analyzed. The daily-dose % reductions observed in VENTURE continued during TRAVERSE in DPL/DPL pts (Wk96: ≤10mg/day: −89%, >10mg/day: −83%) and PBO/DPL pts (Wk96: ≤10mg/day: −70%, >10mg/day: −76%). The % pts achieving 0, <5, or <10mg/day OCS continued to improve throughout TRAVERSE regardless of OCS dose at PSBL. Also, AER was lower in TRAVERSE (range: 0.284–0.599) vs VENTURE (0.463–1.587), and pre-BD FEV1 continued to improve in all subgroups (Table).Conclusion OCS dose reductions were sustained, and improvements in AER and lung function continued during TRAVERSE.FootnotesCite this article as Eur Respir J 2022; 60: Suppl. 66, 3620.This article was presented at the 2022 ERS International Congress, in session “-”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).